Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Malcolm Stacey’s share tip of the year No 1 – buy Advanced Oncotherapy
I can’t exactly remember which New Year shares I tipped last year. But I recall that one of them Zytronic (ZYT) which does wonders with touch technology, was a cracking performer – I got a gold star for it in the performance table!
Though another share I’ve drawn your attention to quite a lot has had a more up and down career. I bought Advanced Oncotherapy (AVO) at around 2p and it’s about 7p now.
But so far, I’m losing quite a bit of dosh on it. That’s all because of that fateful trip I made last April to attend the wonderful UK Investor Show in Westminster.
As the train ride progressed, I bought a load more AVO shares. then noticed that the share, which had snowballed all week, was now approaching 17p. I was about to sell at this point, because such a huge jump is rarely sustained. Then I lost radio signal.
By the time I regained it, the stock had begun a slow journey down. Reasoning, daftly, that it would get a second wind, I hung onto the share. So now I am adrift by quite a bit.
And yet there has not been any spoilers to squash Advanced’s progress. It’s just that little good news has come through, either.
That doesn’t worry me, because with a new technology which is, really, really useful – like zapping cancer tumours – the orders are bound to flood in eventually.
But will the technology, which is based on discoveries at the Hadron Collider project, come to full fruition? Well, a lot of people think so. and I’m told the efficacy of the treatment is already more or less proven.
So if better news comes in 2016 expect that fickle share price to hit 17p again. That would make it a two and half bagger by my reckoning.
We’re good at maths in the Punter’s Return.